AzTrials
AzTrials

Pelvic Organ ProlapseNCT06494982

The Influence of Using Vascularized Vaginal Flap on the Efficacy of Mesh-augmented Sacrospinous Hysteropexy

A study testing Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy and Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy in people with Pelvic Organ Prolapse, run by Saint Petersburg State University, Russia at 1 site in Russia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a prospective randomized controlled trial designed to compare the effectiveness and safety of two methods of pelvic floor reconstruction in patients with pelvic organ prolapse (POP): sacrospinous hysteropexy (SSHP) with synthetic mesh, vascularized anterior vaginal wall flap, anterior colporrhaphy, and… Read more about this study

Who is it for?
Ages 45 to 80 years, women only
Conditions the study is for
Pelvic Organ Prolapse
What is being tested?
Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy and Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteRussia
Study dates
1 May 2024to 1 Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 80 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The subject is a woman with anterior and apical compartment pelvic organ prolapse
  • The age of a subject is 45-80 years
  • Leading point of prolapse is at the level of the hymen or distal to the hymen (Ba, C>=1 according to POP-Q classification)
  • The subject gave written consent to participate in the study
  • The subject is able to evaluate the risks of the treatment and make an independent decision on participation in the study
  • The subject is able to fill up validated questionnaires and come to the control visit after the surgery

Who cannot join

  • The subject has an active urinary tract infection or skin infection in the region of surgery or acute infectious disease
  • The subject had prior hysterectomy
  • The subject has previously diagnosed or currently active cancer
  • The subject has chronic pelvic pain
  • The subject has cervical elongation
  • The subject has gynecological diseases (recurrent uterine bleeding, endometrial hyperplasia, the presence of atypical cells in cervical smears, adenomyosis, multiple uterine myoma)
Show all 9Show fewer
  • The subject is planning pregnancy
  • The subject is unable to visit postoperative check-ups
  • Refusal from participation.

Trial locations and contacts

1 site in 1 country.

Denis Suchkov, MD contact

+79995218976

denis.urolog@yandex.ru

Rustam Shakhaliev, MD contact

+79312368664

rustam.shahaliev@gmail.com

Russia1 site, 1 recruiting
  • Saint-Petersburg State University Hospital

    Saint Petersburg, 190103

    Denis Suchkov, MD, +79995218976, denis.urolog@yandex.ru

    Recruiting

Other trials in Russia

About this study

Official title: The Influence of Augmentation of the Anterior Vaginal Wall With a Vascularized Flap on the Effectiveness of Mesh-augmented Sacrospinous Hysteropexy and Anterior Subfascial Colporrhaphy During Reconstruction of the Pelvic Floor for POP

This is a prospective randomized controlled trial designed to compare the effectiveness and safety of two methods of pelvic floor reconstruction in patients with pelvic organ prolapse (POP): sacrospinous hysteropexy (SSHP) with synthetic mesh, vascularized anterior vaginal wall flap, anterior colporrhaphy, and sacrospinous hysteropexy with synthetic mesh. , anterior colporrhaphy, as well as the impact of surgery on quality of life.

Read the detailed description

BACKGROUND POP is an epidemiologically widespread condition, occurring in 40-60% of women who have given birth. With all the variety of anatomical defects of the pelvic floor, the most common variant is prolapse of the anterior vaginal wall (cystocele).

Of the currently known surgical methods for the treatment of cystocele, anterior colporrhaphy occupies one of the most key places. However, the high recurrence rate of 7-23%, and according to some authors more than 90%, has led to the development of new techniques. In 1997, M. Cosson proposed the "Plastron" method, the essence of which is to close the defect of the pubocervical fascia by fixing a de-epithelialized flap of the anterior vaginal wall to the tendinous arch of the pelvic fascia and then performing anterior colporrhaphy over it. The method was effective in 93.5% of cases in patients with cystocele. At the same time, apical prolapse is present in many women with cystocele. Apical support is important in maintaining normal pelvic floor anatomy. Patients who undergo anterior vaginal wall repair with concomitant repair of the apical defect have a lower risk of reoperation for POP.

There are various methods for restoring apical defects while preserving the uterus. SSHP is the most studied method and was originally performed using sutures. The use of transvaginal mesh for SSHP remains controversial due to the high risk of mesh-associated complications, although many authors report the safety and high effectiveness of the SSHP method using transvaginal mesh. Despite this, the issue of cystocele recurrence after SSHP (with or without mesh) in combination with anterior colporrhaphy remains unresolved.

PREOPERATIVE ASSESSMENT All patients who meet eligibility criteria will undergo a preoperative assessment: medical history, physical and vaginal examination, assessing pelvic organ prolapse according to Pelvic Organ Prolapse Quantification System (POP-Q). All patients will complete questionnaires validated in Russia: Pelvic Floor Disability Index (PFDI-20), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, short form (PISQ-SF), Patient Global Impression of Improvement (PGI-I).

MATERIALS AND METHODS The investigators hypothesis is that is that the use of a deepithelialized vascularized flap of the anterior vaginal wall when performing mesh-augmented sacrospinous hysteropexy and anterior subfascial colporrhaphy reduces the risks of developing relapses of POP in the anterior compartment.

The sample size was calculated taking into account the reported rate of cystocele recurrence using each technique in the literature (6.5% for sacrospinous hysteropexy using vaginal flap vs. 38.7% for mesh-augmented sacrospinous hysteropexy using subfascial colporrhaphy). With a power of 80%, a level of 0,05 and the non-inferiority margin at 15%, the sample size is 50 patients. The investigators assume a drop-out rate of 20%, thus a total of 60 participants will be included in the study.

All enrolled patients will be randomly assigned to SSHP using mesh, vaginal flap and anterior colporrhaphy or SSHP using mesh and anterior colporrhaphy treatment groups in equal ratio the day before the surgery, using computer randomization.

All data will be collected by medical staff not involved in treatment. Collected pre- and postoperative data will be anonymized using unique codes, that patients will receive immediately after randomization.

All surgical interventions will be performed by 3 qualified surgeons. Postoperative follow-up will be performed 6 and 12 months after surgery by 2 researchers, who will be blinded about the type of intervention.

Being tested
Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy, Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
Keywords
pelvic organ prolapse, vaginal repair, vaginal mesh, sacrospinous fixation, vaginal flap
Medical subject headings
Pelvic Organ Prolapse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphyProcedure or surgery

    Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy

  • Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphyProcedure or surgery

    Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy

Study groups in NCT06494982
Study groupRoleWhat they receive
Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphyActive comparatorNot described
Receives: Procedure: Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphyActive comparatorNot described
Receives: Procedure: Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective cure rate

    The patient is considered cured if there is no prolapse beyond the hymen and the cervix is above -1 cm according to POP-Q (0-1 stage)

    Measured: 12 months (1 year)

Secondary outcomes (4)
  1. Satisfaction with the surgery

    Measured through the Patient Global Impression of Improvement questionnaire (PGI-I), validated in Russia. The patient marks the number that best describes her post-operative condition, compared with how it was before surgery. The score ranges from 1 (very much better) to 7 (very much worse).

    Measured: Measured postoperatively at intervals of 6, 12 months postoperatively, up to 100 weeks

  2. The impact of treatment on sexual function

    Measured through the scoring of Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) validated in Russia. The scale evaluates sexual function in patients with urinary incontinence and/or POP. The responses are graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Items 1 - 4 are reversely scored and a total of 48 is the maximum score. The higher scores indicate better sexual function.

    Measured: Measured postoperatively at intervals of 6, 12 months postoperatively, Measured postoperatively at intervals of 6, 12 months postoperatively, up to 100 weeks

  3. The impact of treatment on the quality of life

    Measured through the Pelvic Floor Disability Index (PFDI-20), validated in Russia. The item includes 20 questions. The score ranges from 0 to 300. The higher the score, the worse the outcome.

    Measured: Measured postoperatively at intervals of 6, 12 months postoperatively, Measured postoperatively at intervals of 6, 12 months postoperatively, up to 100 weeks

  4. Observed complications

    Presence of any adverse effects such as: bleeding requiring blood transfusion, haematoma, organ perforation, nerve injury, vaginal scarring and shortening, wound infection, urinary tract infection, pelvic pain, mesh extrusion in the vagina, mesh erosion into the urinary tract, dyspareunia de novo, de novo urgency, atonic bladder, de novo stress urinary incontinence.

    Measured: Measured postoperatively at intervals of 6, 12 months postoperatively, Measured postoperatively at intervals of 6, 12 months postoperatively, up to 100 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2024
  2. Study start1 May 2024
  3. Primary completion1 Oct 2024 (estimated)
  4. Study completion1 Oct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06494982
Sponsor's protocol ID
Vaginal flap
Status last verified
Jul 2024
First submitted
25 Mar 2024
Last updated
10 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy and Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy in people with Pelvic Organ Prolapse, run by Saint Petersburg State University, Russia at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Denis Suchkov, MD (+79995218976, denis.urolog@yandex.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective cure rate (time frame: 12 months (1 year)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in